Our findings are consistent with other published studies including a randomized controlled trial of 18,816 HBV-infected individuals in urban Shanghai, China, where surveillance with alpha-fetoprotein (AFP) and abdominal ultrasounds were performed every 6 months and were associated with a 37% (range 2–59%) reduction in HCC-related mortality [23]. This evidence concerns the gene AFP and hepatocellular carcinoma.